melagatran has been researched along with Obesity in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eriksson, UG; Homolka, R; Peters, GR; Sarich, TC; Svensson, M; Teng, R; Wollbratt, M | 1 |
1 trial(s) available for melagatran and Obesity
| Article | Year |
|---|---|
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Topics: Administration, Oral; Adult; Area Under Curve; Azetidines; Benzylamines; Female; Glycine; Half-Life; Humans; Inactivation, Metabolic; Male; Obesity; Thrombin | 2003 |